Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MITF | O75030 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5263179 | 0.88 | CES1 (0.39) | HSD17B10POLBNPSR1MEN1KMT2A | |
| SCHEMBL782929 | 0.76 | LMNA (0.37) | POLBNPSR1ADORA3TLR9MEN1 | |
| SCHEMBL20889885 | 0.73 | LMNA (0.35) | POLBNPSR1ADORA3KMT2ANPC1 | |
| SCHEMBL10883829 | 0.73 | LMNA (0.35) | HSD17B10POLBNPSR1ADORA3MEN1 | |
| SCHEMBL2697746 | 0.70 | CYP2B6 (0.41) | POLBKMT2ANPC1MITFLMNA | |
| SCHEMBL21081452 | 0.70 | NPC1 (0.36) | POLBNPSR1MGLLMEN1KMT2A | |
| SCHEMBL642226 | 0.69 | — | — | |
| SCHEMBL28817384 | 0.68 | CALM1 (0.40) | MEN1KMT2A | |
| SCHEMBL20542408 | 0.67 | HSD17B10 (0.33) | HSD17B10POLBNPSR1 | |
| SCHEMBL18102199 | 0.67 | KDM4E (0.38) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018193387-A1 | HETEROCYCLIC COMPOUNDS WITH MICROBIOCIDAL PROPERTIES | PI INDUSTRIES LTD. (IN) | 2018-10-25 | — | — | WO | claimed |
| EP-3057586-A1 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2016-08-24 | — | — | EP | claimed |
| WO-2015058160-A1 | BROMODOMAIN INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2015-04-23 | — | — | WO | claimed |
| CN-86106734-A | ARYL PYRIDONES | — | 1987-04-01 | — | — | CN | claimed |
| EP-4709720-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260008788-A1 | AZA-FUSED RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | SUZHOU ARK BIOPHARMACEUTICAL CO LTD (CN) | 2026-01-08 | — | — | US | disclosed |
| EP-4638438-A1 | ALPHA4 BETA7 INTEGRIN ANTAGONISTS AND USES THEREOF | Xinthera, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-12338256-B2 | Aza-tetracyclic oxazepine compounds and uses thereof | GENENTECH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250163030-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | GILEAD SCIENCES, INC. | 2025-05-22 | — | — | US | disclosed |
| US-12263171-B2 | 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use | MERCK SHARP & DOHME LLC (US) | 2025-04-01 | — | — | US | disclosed |
| WO-2024233846-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | LARKSPUR BIOSCIENCES, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| WO-2006012320-A1 | PROCESS FOR THE PREPARATION OF 4-TRIFLUOROMETHYL-2(1H)-PYRIDINONE | DOW AGROSCIENCES LLC (US) | 2006-02-02 | — | — | WO | disclosed |
| EP-1329160-A2 | 4-ACYLAMINOPYRAZOLE DERIVATIVES | Sankyo Company, Limited (JP) | 2003-07-23 | — | — | EP | disclosed |
| EP-0367410-A1 | Aryl pyridones as insecticidal agents | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-05-09 | — | — | EP | disclosed |
| EP-0316185-A2 | N-cyanomethyl-2-pyridinone insecticides | THE DOW CHEMICAL COMPANY (US) | 1989-05-17 | — | — | EP | disclosed |
| EP-0272824-A2 | Chemical compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-06-29 | — | — | EP | disclosed |
| CN-86106734-A | ARYL PYRIDONES | — | 1987-04-01 | — | — | CN | disclosed |
| US-4546191-A | Trifluoromethyl-2-pyridinone or pyridinthione compounds and process for the preparation of the same | ISHIHARA SANGYO KAISHA LTD. (JP) | 1985-10-08 | — | — | US | disclosed |
| US-4546191-A | Trifluoromethyl-2-pyridinone or pyridinthione compounds and process for the preparation of the same | ISHIHARA SANGYO KAISHA LTD. (JP) | 1985-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12338256-B2 | Aza-tetracyclic oxazepine compounds and uses thereof | AZI2, TET3, OXA1L | HSD17B10 1355/4885POLB 1891/4885NPSR1 2385/4885 |
| US-20260008788-A1 | AZA-FUSED RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | PDE4B, PDE4A, CYP4A11 | HSD17B10 590/4885POLB 1119/4885NPSR1 392/4885 |
| US-20250163030-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | PIR, CYP3A43, CYP1A2 | HSD17B10 2713/4885POLB 1716/4885NPSR1 1033/4885 |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | KRAS, NRAS, HRAS | HSD17B10 1079/4885POLB 1305/4885NPSR1 3987/4885 |
| US-12263171-B2 | 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use | ADORA2A, ADORA2B, ADORA3 | HSD17B10 4107/4885POLB 2229/4885NPSR1 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.